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Giant cell myocarditis is an aggressive form of this condition that is typically progressive and unresponsive to usual medical
treatment. Here, we describe a 34-year-old patient presenting with incessant ventricular arrhythmias with hemodynamic
compromise who required prolonged support in intensive care with an intra-aortic balloon pump (IABP). His Coronary arteries
were normal and LV endomyocardial biopsy revealed myocyte necrosis with inﬂammatory inﬁltrate of lymphocytes, eosinophils,
and giant cells suggestive of giant cell myocarditis. He was successfully treated with pulsed intravenous methylprednisolone and
rat antithymocyte globulin (RATG). Despite a good functional cardiac recovery, some months later he developed a ﬂuctuant neck
swelling which ﬁne needle aspirationconﬁrmed as tuberculosis.
1.Introduction
Giant cell myocarditis (GCM) is a rare and often fatal
disorder that used to be a postmortem diagnosis until the
last quarter of the 20th century [1]. With the advent of
endomyocardial biopsy it is now a more recognized ante-
mortem diagnosis. It generally aﬀects healthy and young
individuals with mean age of 42 years (15–60yrs) with no
p r o p e n s i t yf o rg e n d e ro re t h n i c i t y[ 1].
Observations in human tissue and data from rat models
suggestthatgiantcellmyocarditisisanautoimmunedisorder
dependent on CD4 lymphocytes. Up to 20% of GCM cases
occur in individuals with other inﬂammatory or autoim-
mune disorders, especially inﬂammatory bowel disease and
myasthenia gravis [1].
Common presenting symptoms are congestive cardiac
failure(75%),ventriculararrhythmias (14%;incessant forms
are less common but typical), heart block (5%), acute
coronary syndrome (6%), and arterial embolization [1].
Endomyocardial biopsy is usually diagnostic with a
sensitivity of 82–85% [2] and should be considered in all
patients with acute heart failure or ventricular arrhythmia
w h of a i lt oi m p r o v ed e s p i t es t a n d a r dm e d i c a lc a r e .D e s p i t e
advances in the understanding of the condition and the trial
of several diﬀerent treatment strategies, mortality from this
condition remains high with an overall rate of death or heart
transplantation of up to 89% [3].
2.Case Report
We report a case of a 34-year-old Bangladeshi gentleman
who presented with chest pain, increasing shortness of
breath, and palpitations of 1 week’s duration. His past
medical history was unremarkable. Physical examination
revealed a tachycardia of 155bpm and BP of 98/73mmHg.
Initial routine haematology and chemical pathology results
were normal. His admission chest X-ray was also normal.
ECG revealed a broad complex tachycardia (QRS duration
128 milliseconds) with a ventricular rate of 150, RBBB
morphology, and superior right axis deviation consistent
with a fascicular origin (Figure 1).
After initial treatment with IV Amiodarone and Mag-
nesium, he became hypotensive with sustained ventricular2 Cardiology Research and Practice
V1
V1
V2
V3
I
II
III
V4
V5
V6
aVR
aVL
aVF
(a)
V1
V1
V2
V3
I
II
III
V4
V5
V6
aVR
aVL
aVF
(b)
V1
n-219
(c)
Figure 1: ECGs taken during index admission. Normal sinus rhythm. Sustained monomorphic ventricular tachycardia with right bundle
branch block morphology and QRS duration of 130ms suggesting a fascicular origin. Rhythm strip of faster broad complex tachycardia.
tachycardia; so DC cardioversion was required to restore
sinus rhythm. Following this he developed pulmonary
oedema and because of hemodynamic compromise he was
intubated and transferred to intensive care. He was loaded
with amiodarone and given inotropic support but remained
unstable with ongoing episodes of sustained VT. This
was predominantly fascicular VT with occasional broader
complex VT with left bundle branch (LBBB) morphology.
Multiple cardioversions were required.
His echocardiogram showed a dilated left ventricle with
global hypokinesia and an estimated ejection fraction (EF)
of 25% using Simpson’s rule. There was moderate functional
mitral regurgitation and elevated estimated pulmonary
artery pressure.
On day 5 of his admission he became septic with a tem-
perature of 38◦C, C-reactive protein (CRP) of 120mg/dL,
and white cell count (WCC) of 12 × 109/L. He developed
renal (urea 20.3mg/dL, creatinine 153mmol/lit) and hepatic
(bilirubin 20mg/dL, ALP 148IU/lit, ALT 2511IU/lit, and
AST4187IU/lit)impairment. He continued to haveepisodes
of sustained VT with hypotension and oliguria, and so an
intra-aortic balloon pump (IABP) was inserted and a Lido-
caine infusion commenced. He was started on antibiotics
(Vancomycin and Levoﬂoxacin). His condition improved
initially with improvement of renal and hepatic function but
he remained unstable with ongoing episodes of fascicular
VT requiring repeated cardioversion. He was eventually
transferred to a transplant centre where he had a coronary
angiogram (unobstructed coronary arteries) and a blind
LV endomyocardial biopsy. The biopsy revealed myocyte
necrosis with an inﬂammatory inﬁltrate of lymphocytes,
eosinophils, and giant cells suggestive of giant cell myocardi-
tis (Figures2(a) and 2(b)). He was given3 doses of pulsed IV
methylprednisolone and rat antithymocyte globulin (RATG)
with dramatic cessation of his incessant VT followed by a
sustained hemodynamic improvement. He was commenced
on conventional heart failure medication including an ACE-
inhibitor (Lisinopril), a beta-blocker (Carvedilol), and an
aldosterone antagonist (Spironolactone) and hence some of
the functional recovery may have been due to guideline-
based care as well as to immunosuppression.
He was readmitted after 6 months with a ﬂuctuant
swelling in the right anterior triangle of the neck consistent
with a lymph node. Fine needle aspiration demonstrated
Acid Fast Bacilli, and a diagnosis of lymph node tuberculosis
was made. He was treated with a 6-month course consisting
of standard quadruple therapy for 2 months, followed by
4 months of dual antitubercular therapy. It is diﬃcult to
know whether he contracted or reactivated tuberculosis as a
result of his immunosuppression, or whether the GCM was
complicating preexisting tuberculosis.
Immunosuppression with Prednisolone has continued
for a long term although the dose has slowly been reduced to
5mg bd.A cardiac MRI at18-month followupdemonstrated
patchy areas of subendocardial enhancement in the left
ventricle, characteristic of a diagnosis of GCM. At 24-month
followup the patient remains clinically well with no limiting
breathlessness, chest pain, or presyncope. Echocardiography
at 24-month followup showed a dilated LV (end-systolic
diameter 5.1cm, end-diastolic diameter 6.2cm) with mod-
erately impaired LV systolic dysfunction and an ejection
fraction of 45%. On cardiopulmonary exercise testing, he
managed 15 minutes 49 seconds of the modiﬁed Bruce pro-
tocol with an MVO2 of 30.1mL/kg/min and a maximal RER
of 1.09. Repeat Holter monitoring throughout his follow-up
period demonstrated sinus rhythm with a tendency to sinus
bradycardia and short burst of asymptomatic nonsustained
VT of up to 9bts. Dizziness correlating with his bradycardic
episodes precipitated a need to reduce the Carvedilol dose.
In view of this, despite his excellent functional status and
improved left ventricular ejection fraction, he has now been
listed for an implantable deﬁbrillator (ICD).Cardiology Research and Practice 3
Giant cells
Chronic inflammatory cells
Myocytes
(a)
Ragged group of myocytes
Multinucleated giant cells
Cluster of macrophages 
       and lymphocytes
(b)
Figure 2: Histology samples from endomyocardial biopsy. Biopsy
showing active chronic inﬂammation with macrophages and giant
cells. High-power view of granulomatous focus of myocardial
biopsy. Note ill-deﬁned granulomas diﬀerentiating it from TB,
sarcoidosis,and so forth.
3.Discussion
VT is a well-documented clinical presentation of GCM,
and it is usually refractory to antiarrhythmic medications
as well as DC cardioversion [2]. Ventricular tachycardia
in GCM is typically sustained in nature, with moderate
QRS width (120–200ms) and pleomorphic (monomor-
phic/polymorphic, RBBB/LBBB, and superior/inferior axis)
[3]. VT rates are usually relatively slow (average ∼155bpm)
thus not necessarily resulting in hemodynamic compromise.
VT in GCM is due to reentry circuits with myocardial
ﬁbrosis and scar tissue providing a substrate for unidirec-
tional block and reentry. A relatively slow heart rate also
favours reentry circuits.
No antiarrhythmic medications have been proven to
be beneﬁcial in preventing recurrence of VT in GCM,
and as disease progresses quickly with worsening malignant
arrhythmias and refractory heart failure, it is important that
endomyocardial biopsy should be considered early in man-
agement of pleomorphic sustained VT with relatively slower
heart rate once the more common disorders associated with
VT have been excluded. After conﬁrmation of diagnosis,
prompt treatment should be considered to prevent further
complications.
Deﬁnite treatment options for GCM include heart trans-
plantation and immunosuppressive therapy. Heart trans-
plant is supported by a single multicentre study [1, 3–5].
This study analyzed 63 GCM cases from 36 centres. Only
15% of 34 patients who underwent heart transplant died
within 3 years of transplant despite the recurrence of GCM
ingrafts,whereas mediansurvivaltimewasonly12.3months
after symptomonset among 22non-heart-transplant-treated
patients given cyclosporine +/− monoclonal antibodies.
Several case reports and the GCM registry suggest that
certain combinations of immunosuppressant therapy (but
not steroidsalone)can prolongtransplant-free survival, with
the possibility of complete recovery from GCM [1, 3, 5].
In addition to the multicenter GCM registry, the Cleveland
Clinic [6] and the university of Ottawa Heart Institute [7]
have reported their posttransplantation GCM experiences
with similar results. The rate of posttransplantation GCM
recurrence (histological) is 20–25%.
Due to the low incidence of the disease, there is a lack of
randomised data to support any speciﬁc treatment strategy.
However, several immunosuppressants have been used in
registry cases with varying success including cyclosporine,
azathioprine, steroids, and murine monoclonal Ab (OKT-
3). In a study by Shioji et al. [8]i tw a ss h o w nt h a t
IV Ig was highly eﬀective in ameliorating experimentally
induced myocarditis in rats and on this basis RATG has been
tried with some success. Our case report adds to the data
in support of the use of pulsed methyl-prednisolone and
RATG in the treatment of GCM in addition to conventional
guideline-based heart failure treatment. This case report
also highlights the risk of infection (tuberculosis) as a
consequence of lifesaving immunosuppressive therapy. In a
s t u d yb yC o o p e re ta l .[ 9], a risk of infection up to 1 year
following diagnosis was reported in 11 GCM patientstreated
similarly. There is a lack of evidence addressing the risks and
beneﬁt of immunosuppression in this context.
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